Journal
NATURE COMMUNICATIONS
Volume 8, Issue -, Pages -Publisher
NATURE PORTFOLIO
DOI: 10.1038/ncomms14687
Keywords
-
Categories
Funding
- Bayer A.G. [2012-08-0765]
- Fundacao para a Ciencia e a Tecnologia (FCT) [UID/BIM/04773/2013, 1334]
- FCT [SFRH/BPD/84634/2012, SFRH/BPD/100434/2014]
- FCT Investigator Program contract from the Foundation for Science and Technology of Portugal [IF/00614/2014]
- ProRegem grant [PD/BD/114258/2016]
- Fundação para a Ciência e a Tecnologia [SFRH/BPD/100434/2014, SFRH/BPD/84634/2012] Funding Source: FCT
Ask authors/readers for more resources
Intrinsic and acquired resistance to chemotherapy is the fundamental reason for treatment failure for many cancer patients. The identification of molecular mechanisms involved in drug resistance or sensitization is imperative. Here we report that tribbles homologue 2 (TRIB2) ablates forkhead box O activation and disrupts the p53/MDM2 regulatory axis, conferring resistance to various chemotherapeutics. TRIB2 suppression is exerted via direct interaction with AKT a key signalling protein in cell proliferation, survival and metabolism pathways. Ectopic or intrinsic high expression of TRIB2 induces drug resistance by promoting phospho-AKT (at Ser473) via its COP1 domain. TRIB2 expression is significantly increased in tumour tissues from patients correlating with an increased phosphorylation of AKT, FOXO3a, MDM2 and an impaired therapeutic response. This culminates in an extremely poor clinical outcome. Our study reveals a novel regulatory mechanism underlying drug resistance and suggests that TRIB2 functions as a regulatory component of the PI3K network, activating AKT in cancer cells.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available